Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications
Gaia Griguolo(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Grazia Maria Vernaci(University of Padua), Rocco Cappellesso(University of Padua), Francesca Schiavi(Istituto Oncologico Veneto), Tommaso Giarratano(Istituto Oncologico Veneto), Silvio Bicciato(University of Modena and Reggio Emilia), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Michele Bottosso(University of Padua), Simon Spazzapan(Centro di Riferimento Oncologico), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Enrico Tagliafico(University of Modena and Reggio Emilia), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Anna Tosi(University of Padua), Aleix Prat(University of Padua), Federica Miglietta(University of Padua), Maria Vittoria Dieci(University of Padua), Daniele Generali(University of Trieste)
Cited by 1
Related Papers
The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
|Cell|2011|1.4k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A MicroRNA Targeting Dicer for Metastasis Control
|Cell|2010|665